Abstract
Genetic variation in the interferon regulatory factor 5 (IRF5) gene affects systemic lupus erythematosus (SLE) susceptibility. However, association is complex and incompletely defined. We obtained fourteen European sample collections with a total of 1383 SLE patients and 1614 controls to better define the role of the different IRF5 variants. Eleven polymorphisms were studied, including nine tag single nucleotide polymorphisms (SNPs) and two extra functional polymorphisms. Two tag SNPs showed independent and opposed associations: susceptibility (rs10488631, P<10−17) and protection (rs729302, P<10−6). Haplotype analyses showed that the susceptibility haplotype, identified by the minor allele of rs10488631, can be due to epistasis between three IRF5 functional polymorphisms. These polymorphisms determine increased mRNA expression, a splice variant with a different exon 1 and a longer proline-rich region in exon 6. This result is striking as none of the three polymorphisms had an independent effect on their own. Protection was independent of these polymorphisms and seemed to reside in the 5′ side of the gene. In conclusion, our results help to understand the role of the IRF5 locus in SLE susceptibility by clearly separating protection from susceptibility as caused by independent polymorphisms. In addition, we have found evidence for epistasis between known functional polymorphisms for the susceptibility effect.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Croker JA, Kimberly RP . SLE: challenges and candidates in human disease. Trends Immunol 2005; 26: 580–586.
Pascual V, Farkas L, Banchereau J . Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676–682.
Nath SK, Kilpatrick J, Harley JB . Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 2004; 16: 794–800.
Croker JA, Kimberly RP . Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17: 529–537.
Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528–537.
Demirci FY, Manzi S, Ramsey-Goldman R, Minster RL, Kenney M, Shaw PS et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 2006; 71: 308–311.
Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A et al. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 2007; 16: 579–591.
Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550–555.
Kozyrev SV, Lewen S, Reddy PM, Pons-Estel B, Witte T, Junker P et al. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1234–1241.
Shin HD, Sung YK, Choi CB, Lee SO, Lee HW, Bae SC et al. Replication of genetic effects of interferon regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Res Ther 2007; 9: R32.
Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 2005; 280: 21078–21090.
Consortium IH . A haplotype map of the human genome. Nature 2005; 437: 1299–1320.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610–2615.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–723.
Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104: 6758–6763.
Li SS . Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem J 2005; 390: 641–653.
Barnes BJ, Moore PA, Pitha PM . Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382–23390.
Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002; 21: 2914–2918.
Hu G, Mancl ME, Barnes BJ . Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005; 65: 7403–7412.
Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007; 104: 3402–3407.
Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280: 17005–17012.
Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature 2005; 434: 243–249.
Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K et al. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem Biophys Res Commun 2007; 354: 1045–1051.
Barnes BJ, Kellum MJ, Field AE, Pitha PM . Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002; 22: 5721–5740.
Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM et al. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004; 279: 45194–45207.
Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum 2004; 50: 2590–2597.
Ferreiros-Vidal I, D'Alfonso S, Papasteriades C, Skopouli FN, Marchini M, Scorza R et al. Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe. Genes Immun 2007; 8: 138–146.
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.
Schneider S, Roesli D, Excoffier L . Arlequin ver 2000 A: Software for Population Genetics Data Analysis. Genetics and Biometry Laboratory, University of Geneva: Switzerland, 2000.
Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.
Goudet J, Raymond M, de Meeus T, Rousset F . Testing differentiation in diploid populations. Genetics 1996; 144: 1933–1940.
Acknowledgements
Cristina Fernandez-Lopez and Marta Picado have provided outstanding technical assistance. This work has been supported by Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (Spain), Grants 04/1651 and 06/0620 that are partially financed by the FEDER program of the EU and by Grants from the Xunta de Galicia. SR and CD were supported by Grant 00023728 of the Ministry of Health of the Czech Republic. RES and TW were supported by BMBF, KN Rheuma C2.12. Work by SD’A was supported by Telethon (Grant E1221) and the CARIPLO Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interests
The authors have no conflict of interests to declare in relation with this manuscript.
Supplementary information accompanies the paper on Genes and Immunity web site (http://www.nature.com/gene)
Supplementary information
Rights and permissions
About this article
Cite this article
Ferreiro-Neira, I., Calaza, M., Alonso-Perez, E. et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 8, 429–438 (2007). https://doi.org/10.1038/sj.gene.6364407
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gene.6364407
Keywords
This article is cited by
-
Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus
Scientific Reports (2019)
-
Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies
Arthritis Research & Therapy (2013)
-
Association of rs10954213 polymorphisms and haplotype diversity in interferon regulatory factor 5 with systemic lupus erythematosus: A meta-analysis
Journal of Huazhong University of Science and Technology [Medical Sciences] (2013)
-
Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines
Arthritis Research & Therapy (2011)
-
Pharmaceutical sciences in 2020
Nature Reviews Drug Discovery (2010)